ClinicalTrials.gg
RecruitingNCT06874517Updated Mar 26, 2025

Second Toe Length and Hallux Valgus: Greek vs. Egyptian Foot

An observational study in Hallux Valgus, sponsored by Beylikduzu State Hospital. Recruiting at 1 site in Turkey. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Beylikduzu State Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Ages
60 Years to 80 Years
Sex
All
01

Study summary

A total of 150 patients aged 60-80 years with existing foot radiographs will be included in the study. Radiographic evaluations will include measurements of the hallux valgus angle, first intermetatarsal angle, and the metatarsal and phalanx lengths of the first and second toes. The ratio of the second toe phalanx length to the first toe phalanx length will be calculated and recorded. The relationship between the hallux valgus angle, toe lengths, and their ratios will be analyzed using statistical methods.

02

Conditions studied

  • Hallux Valgus

Browse trials for

03

In context

Hallux Valgus

157 studies on the registry are indexed under Hallux Valgus; 36 are open to participants now.

This study's planned enrollment of 150 is above the median of 60 across 35 observational studies indexed under Hallux Valgus.

Browse Hallux Valgus studies →

Lead sponsor

Beylikduzu State Hospital is the lead sponsor of 23 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population will consist of 150 patients aged 60-80 years who have existing foot radiographs suitable for measurement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 60-80 years
  • Presence of foot radiographs suitable for measurement
  • No history of prior foot surgery

Exclusion criteria

Exclusion Criteria:

  • History of foot trauma or fractures
  • Previous foot or toe surgery
  • Presence of congenital foot deformities
  • Neurological or rheumatologic conditions affecting foot structure
  • Severe osteoarthritis or other degenerative foot diseases visible on radiographs
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Hallux Valgus Angle

    The angle between the first metatarsal and the proximal phalanx of the first toe, measured on radiographs. Higher values indicate greater hallux valgus severity.

    Time frame: 0 day

Secondary outcomes

  1. First Intermetatarsal Angle

    The angle between the first and second metatarsal bones, measured on radiographs. Higher values are associated with increased deformity.

    Time frame: 0 day

  2. First Toe (Hallux) Metatarsal and Phalanx Lengths

    The length of the first metatarsal and its phalanges, measured on radiographs.

    Time frame: 0 day

  3. Second Toe Metatarsal and Phalanx Lengths

    The length of the second metatarsal and its phalanges, measured on radiographs.

    Time frame: 0 day

  4. Second Toe to First Toe Phalanx Length Ratio

    The ratio of the second toe phalanx length to the first toe phalanx length, calculated to assess relative toe length differences.

    Time frame: 0 day

07

Study locations

1 of 1 sites recruiting
  • Beylikdüzü State Hospital
    Istanbul, Beylikdüzü 34147, Turkey
    Recruiting
    • Büşra Şirin · Contactbsrn080@gmail.com · 02124443322
    • Büşra Şirin Ahısha, MD · Principal investigator
    • Nurdan Paker, Prof · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Apr 2025, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2025
First posted
Mar 13, 2025
StartActual
Mar 10, 2025
Primary completionEst.
Apr 10, 2025
CompletionEst.
Apr 10, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874517
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Mar 13, 2025
Start date
Mar 10, 2025
Primary completion
Apr 10, 2025 (estimated)
Completion
Apr 10, 2025 (estimated)
Last update
Mar 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion